Is afatinib still on patent uk?

Short answer: The situation is mixed. The core afatinib (BIBW2992) patent family has largely expired in the UK, but there can still be active rights in the UK on other aspects (such as salt/formulation, specific methods of use, or separate US/EU patents that cover related aspects) and there may be an SPC tied to the product that extends protection.

If you need a precise answer, you should check current UK status for:
- The main afatinib patent family (search “BIBW2992” or “afatinib” in patent databases like Espacenet and look at the UK national phase status).
- Any UK SPCs for afatinib (especially tied to the product GILOTRIF/Gilotrif products) on the UKIPO or EUR-Lex SPC registers.
- Any other derivative patents (salts, formulations, methods of use) that might still be in force.

Would you like me to look up the latest UK patent and SPC status for afatinib and summarize which rights are in force and their expiry dates? If yes, I can guide you through or provide a current snapshot.